drugset / Trial / NCT04485065
Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS
NaSingle-groupOpen-labelTreatment
Summary
The study is to evaluate safety and efficacy of IBI188 in combination with azacitidine (AZA) as a first-line treatment in subjects with newly diagnosed higher risk myelodysplastic syndrome
Timeline
- Start
- 2020-09-30
- Primary completion
- 2023-12-30
- Completion
- 2024-08-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI188 | Monoclonal antibody | 30 mg/kg | Intravenous |
| Background | Azacitidine | Other / unclassified | — | Other |